Insights & Analysis

Practical perspectives on AI governance, intelligent automation, and regulatory strategy for life sciences.

Quality10 min read

Deviation Investigation Quality Is a Top Agency Finding — AI Can Help, but Should Companies Invest in AI Projects to Build This In-House?

Deviation investigation quality is consistently among the top FDA and EU MDR audit findings. AI offers real solutions — but the strategic question isn't whether to use AI. It's whether building it in-house is the right investment when regulatory domain experts have already solved it.

2026-03-05Read more →
AI Governance8 min read

AI Governance in Life Sciences: What Regulators Expect in 2026

From the EU AI Act to FDA draft guidance on AI/ML, regulated companies face a new reality. Here's the practical governance framework you need — not the theoretical one consultants sell.

2026-03-05Read →
Quality6 min read

Why Your QMS Is Already Obsolete (And What to Do About It)

Quality Management Systems were designed for a world of paper and periodic audits. AI-driven quality intelligence is the next evolution — and it's already here.

2026-03-04Read →
Cybersecurity7 min read

Pharma Cybersecurity: Beyond the Checkbox Audit

Life sciences companies treat cybersecurity like a compliance exercise. The threat actors targeting your clinical data and manufacturing systems don't care about your audit score.

2026-03-03Read →
Regulatory9 min read

SaMD + AI: What the FDA Actually Wants to See

Software as a Medical Device meets artificial intelligence. The intersection is where the biggest regulatory opportunities — and risks — live for diagnostics and digital health companies.

2026-03-01Read →
Cybersecurity9 min read

Cybersecurity in Pharma: Why GxP-Aware Threat Detection Changes Everything

Pharmaceutical cybersecurity isn't just IT security — it's a quality issue. When threat actors target your manufacturing systems, LIMS platforms, and clinical databases, traditional security tools miss the GxP context that matters most.

2026-03-06Read →
AI Governance10 min read

AI Governance in Life Sciences: A Practical Framework for 2026

The EU AI Act is here. FDA guidance is evolving. Life sciences companies need AI governance frameworks that work operationally — not just on paper. Here's what effective AI governance looks like in practice.

2026-03-06Read →
Quality9 min read

Automating Deviation Management: How AI Reduces CAPA Cycle Times by 50%

Deviation investigations and CAPA workflows consume more quality bandwidth than any other activity. AI-powered automation doesn't replace quality professionals — it makes them 10x more effective.

2026-03-06Read →
Manufacturing10 min read

The Real Cost of Manual Batch Record Review (And How to Fix It)

Pharmaceutical companies spend thousands of hours reviewing batch records manually — catching formatting errors, missing signatures, and data entry mistakes. AI-assisted review changes the economics entirely.

2026-03-06Read →
Clinical11 min read

Pharmacovigilance AI: From Adverse Event Processing to Signal Detection

Adverse event case processing is labor-intensive, error-prone, and difficult to scale. AI-powered pharmacovigilance doesn't just speed up ICSR processing — it transforms safety monitoring from reactive to predictive.

2026-03-06Read →
Corporate9 min read

The Fractional CIO for Pharma: Why Life Sciences Companies Are Rethinking IT Leadership

Mid-size pharma and biotech companies face a CIO gap: too big for no IT leadership, too small for a full-time executive. The fractional CIO model changes the economics — and AI agents are changing it again.

2026-03-06Read →
AI Governance10 min read

EU AI Act and Pharmaceutical Companies: What You Need to Know in 2026

The EU AI Act is now enforceable. Many pharma AI systems are classified as "high-risk." Here's the practical compliance roadmap — not the consultant version with 40-page policy documents.

2026-03-06Read →
Quality11 min read

GAMP 5 and AI: A Practical Guide to Validating Intelligent Systems

GAMP 5 categories don't map cleanly to AI/ML systems. Here's the practical framework pharmaceutical companies are using to validate AI while satisfying FDA and EMA expectations.

2026-03-06Read →
Regulatory10 min read

Regulatory Intelligence: How AI is Transforming Submission Strategy

Regulatory intelligence used to mean manually tracking guidance documents and FDA databases. AI-powered regulatory monitoring doesn't just track changes — it predicts impacts and suggests strategic responses.

2026-03-06Read →

Stay Informed

Get the latest insights on AI governance, regulatory strategy, and intelligent automation delivered to your inbox.